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A series of 176 archival cervical intraepithelial neoplasia (CIN) was analysed for the presence, viral load and integration status of ‘high-
risk’ types of human papillomavirus (HR-HPV). The samples were assayed using newly developed methods based on real-time PCR.
Two methods for the extraction of DNA from the paraffin-embedded biopsies were compared: a protocol based on the MagNA
pure system (Roche) and a Qiagen spin column kit (Qiagen). It was possible to amplify 94% (166) of the samples. Of these, 36, 63
and 80% of the CIN I, II and III cases contained HR-HPV. HPV 16 was the most prevalent, and was found in 20, 28 and 46% of the
CIN I, II and III cases, respectively. The second most frequent HR-HPV was type 33 group, and in CIN II it was as prevalent as HPV 16.
The median number of copies of HR-HPV per cell was not significantly different in the CIN I, II and III cases, but there was a wide
range of viral load values over several magnitudes, regardless of the grade of CIN. All samples were found to contain integrated forms
of HPV 16, frequently mixed with an episomal form.
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Intensive research has provided evidence for a central, causal role
of certain types of HPV in the development of invasive cervical
carcinoma (Schiffman et al, 1993; Davidson et al, 1994;
Walboomers et al, 1999; Bosch and Munoz, 2002). The presence
of high-risk HPV-DNA identifies both women with disease and
those who are at a particular risk of progression to disease
(Nobbenhuis et al, 1999). Persistent infection with high-risk types
of HPV (HR-HPV), especially type 16, is regarded as the principal
risk factor in the development of squamous cervical lesions or
squamous cervical cancer (Munoz et al, 2003). However, most
infections with HPV regress spontaneously, and, for the cases that
do progress to cancer, a long period of latency is normally
observed. HPV infections are prevalent and often transient among
younger women, with a peak of 20–25% at 20–24 years of age.
With increasing age, there is a decline in the prevalence of HPV
to about 7% at 35 years of age (Soutter and Fletcher, 1994). It is
likely that HPV-positive women at that age represent a subset of
individuals who do not manage to clear their infections
spontaneously. Thus, the persistence of a high-risk HPV infection
is associated with the risk of developing cervical intraepithelial
neoplasia (CIN).
A high prevalence of transient infections makes detection of
the virus an inefficient means of identifying women at risk of
developing cervical cancer (Ho et al, 1998; Jacobs et al, 2000).
Viral load has been suggested as a marker of nontransient
infection; a high HPV load in archival Pap smears with normal
cytology had a considerably higher risk of developing carcinoma
in situ, and even cervical squamous carcinoma (Josefsson et al,
2000; Lorincz et al, 2002; Dalstein et al, 2003; Gravitt et al, 2003;
Moberg et al, 2004). Recently, it has been concluded that HPV load
is a type-dependent risk marker for invasive carcinoma (Moberg
et al, 2005). Furthermore, it has been suggested that there is an
association between a high viral load and the persistence of
infection with HPV (Ho et al, 1998).
The integration status of high-risk HPV in premalignant cervical
lesions might be a further promising risk marker for progression of
cervical cancer (Lazo, 1997; Kalantari et al, 1998). Viral DNA
integration into the host cell genome usually disrupts the E1 and E2
open reading frames, while those of E6 and E7 remain intact
(Kalantari et al, 1998, 2001). The deletion of E2 ORF, due to the
integration, results in disruption of expression of E2 protein and
subsequent upregulation of the transcription of the oncogenic E6 and
E7 proteins (Romanczuk and Howley, 1992). Continuous production
of oncogenic E6 and E7 proteins contribute to the malignant state in
infected tissue. Thus, viral integration into the host genome is
possibly another critical event for malignant transformation.
In the present study, our aim was to evaluate the frequency of
HR-HPV types and viral load in a series of paraffin-embedded
biopsies with pre-neoplastic and neoplastic lesions. Based on these
data, we sought to determine if type distribution and viral loads of
different HR-HPV types in CIN I–III lesions show any significant
differences. We also evaluated any differences in the integration
status of HPV 16, as a function of the grade of CIN.
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Specimens from 176 biopsies, which represented CIN I–III lesions,
obtained between 2002 and 2003, were collected from the
Department of Pathology, Karolinska University Hospital at
Huddinge. The biopsies were fixed in neutral buffered formalin
and embedded in paraffin. Serial sections were cut from each
block. The first was stained with haematoxylin-eosin and evaluated
histopathologically, whereas the following were used for the
preparation of DNA and the HPV test. The biopsies were grouped
according to the morphological diagnosis and types of HPV
present. The diagnosis of all cases was reviewed and reconfirmed
by one pathologist.
Extraction of DNA from tissue sections
To optimise the DNA extraction method for our study, two
different DNA-extraction protocols were compared.
Extraction using specific magnetic glass particles (MGPs) to bind
DNA (Roche MagNA pure kit) Protocol A is based on binding the
isolated DNA from tissue samples to the surface of specific MGPs.
This procedure is automated and performed by using the MagNA
Pure LC system (Roche).
The paraffin-embedded (formaldehyde-fixed) tissue sections
were deparaffinised with xylene and absolute ethanol. To melt the
paraffin, the paraffin-embedded tissue sections were incubated at
651C for 10min, and, subsequently, 1ml xylene and 500ml absolute
ethanol were added and mixed gently. After centrifugation at
14000rpm for 2min, the supernatant was discarded and 1ml
absolute ethanol was added. After a new 2-min centrifugation at
14000rpm, the pellet was dried for 10–15min using a Speed Vac
vacuum drier.
The dried pellet was re-suspended in a 130ml tissue lysis buffer
and 20ml proteinase K, and was subsequently incubated at 561C
overnight. The cell suspension was mixed with a 350ml cell lysis
buffer in a sample cartridge, and then loaded into the MagNa Pure
instrument. The other reagents, that is, MGPs, which bind the total
DNA from the lysed cell suspension, proteinase K, and a wash and
elution buffer, were also loaded into the instrument. The extracted
DNA was eluted with a 50ml elution buffer.
Extraction using a specific spin column to bind DNA (Qiagen
kit) Protocol B is a manual DNA extraction method, which is
based on the QIAamp Spin Column kit (Qiagen).
The paraffin-embedded tissue sections were deparaffinised by
the procedure described above. After addition of 1ml xylene, the
tube was incubated at room temperature for 30min and
subsequently centrifuged at 14000rpm for 5min. This step was
repeated once, after which 1ml absolute ethanol was added to the
tube, followed by centrifugation at 14000rpm for 5min. The pellet
was dried in the Speed Vac for 10–15min and was then
resuspended in a 180ml tissue lysis buffer and 20ml proteinase K.
After incubation of the solution at 561C overnight, a 200ml cell
lysis buffer was added. A new incubation at 701C for 10min was
carried out before the addition of 200ml 95% ethanol. The mixture
was then applied to the QIAamp spin column. After centrifugation
of the column at 8000rpm for 1min, the column was washed twice
with a 500ml wash buffer AW1 followed by AW2. The purified
DNA was eluted with 50ml distilled water.
Detection and quantification of HPV by the ‘QUANTOVIR
HPV’ system
Extracted DNA from the MagNA pure was subsequently quanti-
fied, and HR-HPV typed, by using the ‘QUANTOVIR HPV’
detection and quantification system as described by Moberg et al
(2003).
The ‘QUANTOVIR HPV’ detection and quantification kit was
used for preparation of the Master Mix. The real-time PCR
reaction was performed in a total volume of 25ml (22ml Master Mix
and 3ml DNA template), and with the use of optical 96-well micro-
plates were used. The Master Mix contained 1  PCR buffer –
200mM each of dATP, dCTP and dGTP and 400mM dUTP – 3.5mM
MgCl2,1 0   G-carboxy-X-rhodamine,6-Rox, and 0.625U Taq
DNA polymerase final concentrations in sterile water. The PCR
amplification program consisted of an initial holding step of
10min at 951C, followed by a two-step cycle of 15s at 951C and
1min at 571C for 40 cycles. Three parallel reactions per sample
were performed: no. 1 quantified HPV 16, 31, 18 and 45 (the last
two together); no. 2 quantified HPV 33, 35, 39, 52, 58 and 67 (HPV
33, 52, 58 and 67 together); no. 3 quantified the single copy human
gene for hydroxymethylbilane synthase. A total of six nontemplate
control reactions, which consisted only of PCR components
without template DNA, were used as negative controls to ensure
that the reagent mix was free of contamination. The assay was
performed by using the ABI PRISM 7700 Sequence Detection
System, running the 1.6.3 version of the SDS program (Applied
Biosystems).
Since the ABI 7700 software could not quantify three different
fluorophores in the same reaction, a separate QUANTOVIR
algorithm was developed, using the MATLAB program vers.
5.2.1, directly coupled to the data collection program of the ABI
7700 apparatus. This was used for calculation of the threshold
cycle, and conversion of the data into HPV copy numbers per cell.
The number of cells was calculated from the copy numbers of a
single copy human gene (hydroxymethylbilane synthase), and this
and other calculations were performed automatically by the
specially developed software.
The established linear dynamic range of the method is 10
2–10
7
copies of HR-HPV per genomic DNA equivalent (Moberg et al,
2003).
HPV integration status
The recently developed real-time PCR-based integration method
of Peitsaro et al (2002) was performed by using the ABI prism
7700 Sequence Detection system and the TaqMan PCR Master Mix
(PE Applied Biosystems, Perkin-Elmer). The basic principle of the
method is to use specific primers and probes for separate assays
of the region (‘hinge region’) of the E2 ORF, most often deleted
during integration, and part of the E6 ORF. The latter ORF is
always retained in the integrated virus. The E6 probe was labelled
with FAM at the 50- and TAMRA at the 30-end, while the E2 probe
was labelled with VIC at the 50- and TAMRA at 30-end. The final
concentrations of primers and probes in a total of 50ml of reaction
mixture were 0.3 and 0.1mM, respectively. Two standard curves for
E6 and E2 were obtained by amplification of a dilution series of
one million to 10 copies of a clone of the entire HPV 16 genome in
pBR322. There was a linear relationship between the threshold
cycle values plotted against the log of the copy number over the
entire range of dilutions (data not shown). The 96-well optical
plate was used to run reactions. In each experiment, samples were
loaded in duplicate and three negative controls were included.
DNA from the SiHa cell line, containing one copy of fully
integrated HPV 16, was also used as a control for full integration in
these experiments. No E2 signal should be produced, since the
assayed region of E2 is deleted in SiHa cells.
RESULTS
The study comprises 166 cases: among these 50 (30%) CIN I, 60
(36%) CIN II and 56 (34%) CIN III. The mean age of women with
CIN I was 39.6, in women with CIN II was 33.3 and in women with
CIN III was 34.7.
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A comparison between the Qiagene and Magna Pure kits showed
that Magna Pure provided higher DNA yields than Qiagene for the
extraction of paraffin-embedded tissue sections. The MagNA pure
system has further advantages in its semi-automation and
quickness. It has been used throughout this study.
Frequencies of HR-HPV
Of the 176 samples analysed with the ‘Quantovir HPV’ system, 10
were totally negative, that is, no signal was obtained from the
human gene. The frequencies of the different types of HR-HPV in
the remaining 166 samples, from different stages of CIN, are
summarised in Table 1 and Figure 1.
There was a steady increase in the frequency of HR-HPV from
CIN I to III. Of the CIN III samples, 45 (80%) were positive for HR-
HPV. As shown in Figure 1, the increased frequencies of HR-HPV
were due to increase in the number of positive cases with HPV 16,
18/45 and 33 groups (HPV 33, 52, 57, 58), while the number of
positive cases with HPV 31 and 39 was constant. As could be
expected, the oncogenic HPV 16 predominated at all stages of CIN:
20, 28 and 46% at CIN I, II and III, respectively.
However, the high proportion (23%) of the HPV 33 group in the
biopsies from CIN II seemed almost as high as that for HPV 16
(Table 1, Figure 1). No HPV 35 was found in this material.
Viral loads
HR-HPV The viral loads obtained for HR-HPV in the different
grades of CIN are summarised in Figure 2. There was a distribution
of viral load values of several orders of magnitude at all grades of
CIN. The span of values of copies of HR-HPV per cell ranged from
0.14 to 8400. The mean values of the copies per cell were: CIN I – 8;
CIN II – 17 and CIN III – 6. However, by using the one-way
ANOVA analysis, there was no significant difference determined
between these mean values.
HPV 16
Since HPV 16 is the most predominant type in this material, as well
as in cervical squamous carcinomas, viral load values were
examined separately for this type. As for HR-HPV in general,
there was an equally broad distribution of viral loads (Figure 3).
The mean values of copies per cell were: CIN I – 2, CIN II – 18 and
CIN III – 6. Moreover, in this case, there was no significant
difference between the mean values as determined by the one-way
ANOVA analysis.
Viral integration
A specially designed real-time PCR method (Peitsaro et al, 2002)
was used to estimate HPV 16 integration by comparing viral loads
from the parts of the E2 ORF that are mostly deleted during
integration, and those of the E6 ORF. The latter gives an estimate
of the total number of HPV 16 genomes, episomal and integrated.
Table 1 Frequency of HR-HPV types in samples from different CIN
grades
CIN grade
Frequency, % of DNA-positive samples I II III
HR-HPV 36 63 80
HPV 16 20 28 46
HPV 33 group 4 23 21
HPV 18/45 2 7 9
HPV 31 6 3 7
HPV 39 6 5 5
HPV 35 0 0 0
CIN¼cervical intraepithelial neoplasia. Total number of human DNA-positive
samples (166) were: CIN I, 50; CIN II, 60; CIN III, 56.
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Figure 1 Frequencies of the HR-HPV types in samples from different CIN grades. Frequencies of the different types of HR-HPV in total 166 samples,
distributed over the three CIN grades, are shown. CIN I – chequered bars, CIN II – striped bars, CIN III – blank bars.
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load determination, were found to contain integrated virus
genomes. However, there was a higher proportion of cases with
no detectable copies of the E2 gene, indicating complete
integration (Table 2), at the CIN III stage (36%) than at the CIN
I (25%) and CIN II (7%) stages. Among the cases showing E2/E6
ratios less than 1.0, presumably containing episomal and
integrated virus genomes, the relative contents of the two forms
varied considerably (Figure 4). The average ratios of episomal and
integrated forms were not significantly different in the three stages
of CIN, as determined by the one-way ANOVA analysis. However,
if a cutoff value is introduced at a ratio of 1:100 of episomal and
integrated forms, respectively, there are significantly more cases
below this value in CIN III (horizontal line in Figure 4).
DISCUSSION
Epidemiological and molecular biological studies have shown that
infection with high-risk HPV is the most important aetiological
agent in the pathogenesis of cervical cancer (Bosch et al, 1995).
At present, more than 99% of the squamous cell tumours are
considered to harbour oncogenic types of HPV (Walboomers et al,
1999). HPV 16, 18, 45, 31 and 33 are the most frequently identified
viruses in CIN II–III and cervical squamous cell carcinomas
(Munoz et al, 2003).
In our study, a stored formalin-fixed and paraffin-embedded
material was used for the Quantovir test. We investigated the
presence of different types of HPV and the viral loads in women
with CIN I–III. The Quantovir test, a quantitative assay which is
applicable for clinical use and capable of detecting a range of
high-risk types of HPV involved in cervical carcinogenesis, has been
previously described in detail (Moberg et al, 2003). The system has
many technical advantages: a high sensitivity, high specificity and
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Figure 2 HR-HPV viral load and CIN grade. Distribution of the log
values for viral load at different CIN grades is shown. The horizontal line
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Figure 3 HPV 16 viral load and CIN grade. Distribution of the log values
is shown for viral load at different CIN grades. The horizontal line denotes
average log values. The table contains the log per cell at the different CIN
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Figure 4 HPV 16 integration status at different CIN grade. Integration
status is calculated from the ratios of copy numbers for gene E2 divided by
the same values for gene E6. The E2 values are related to the number
of episomal copies, whereas the E6 values arise from the total number of
HPV 16 copies. The values are shown in log form. The top horizontal bar
indicates the log ratio expected from purely episomal form (E2/E6
ratio¼1). The horizontal line in the upper graph at log 2, indicates an
integration status, where there is one episomal form for a total of 100
copies of HPV 16.
Table 2 Number of totally integrated HPV 16 in samples from different
CIN grades
CIN grade
Totally I II III
Number of samples 8 15 25 48
Totally integrated 2 1 9 12
Totally int. (%) 25 7 36
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molecules in each reaction tube is possible by using a newly
developed software to calculate copies of HPV-DNA per cell.
Identification and a viral load estimate of HPV types in a reaction
involving other types is reliable as long as it represents at least
1–10% of the amount of the main HPV type (Moberg et al, 2003).
The sensitivity of the assay decreased when the ratio between
the types of HPV was less than 1:100. Furthermore, several
techniques for analysis of HPV are available, causing variations
with respect to both sensitivity and specificity. Although the
linear dynamic range of the method was certified only down
to 100 copies HR-HPV per cell equivalent (Moberg et al, 2003),
compared to the five copies described by Gravitt et al (2003),
quantification was also possible below that level. However, these
figures should be regarded as approximative. We compared two
extraction methods the MagNA pure system (Roche) and a Qiagen
spin column kit (Qiagen). We found that the MagNA pure kit was
more sensitive and provided the highest DNA yields from the
material.
By using the Quantovir test, we identified five different
oncogenic types of HPV (16, 31, 18/45, 33, 39) in our material.
As could be expected, the oncogenic HPV 16 predominated at all
stages of CIN: 20, 28 and 46% at CIN I, II and III, respectively. The
most obvious findings were that HPV types 31 and 39 did not
occur more frequently in higher degrees of CIN, and that the
frequency (23%) of the HPV 33 group in the biopsies from patients
with CIN II seemed almost as high as that for HPV 16. In previous
studies, in which the sensitive PCR technique for detection and
typing of HPV DNA was used, it was reported that HPV 16 is the
most common type, followed by types 31 and 18. Even in a general
population of 32–38-year-old healthy women, HPV 16 is the most
prevalent type (2.2%) (Forslund et al, 2002).
Earlier studies have described the relative frequency of the most
common oncogenic types of HPV in pre-invasive cervical lesions
and cervical carcinoma. Our results demonstrated a predominance
of HPV 16, followed by HPV 33. However, it is also of importance
to identify the less prevalent and rare types of HPV in different
pre-invasive lesions since the types of HPV identified may vary
geographically.
Several studies have published reports investigating viral load’s
association with risk for cervical cancer and its precursors. The
majority use HCII to measure viral load, and while some find viral
load to be positively associated with increased risk for prevalent or
incident disease (Sun et al, 2001, 2002; Dalstein et al, 2003) others
do not (Lorincz et al, 2002; Sherman et al, 2002). Recent studies
employing quantitative PCR to estimate HPV load show associa-
tion between viral load and prevalent or incident disease more
consistently (Ylitalo et al, 2000; Gravitt et al, 2003; Schlecht et al,
2003). Considerable viral-load variation has been observed within
histopathological grades of the disease (Swan et al, 1999), making
it hard to define uniform cutoff values. In addition, viral loads
have been reported to be associated with lesion size rather than
lesion severity.
It is noteworthy that in our study this is the first time that viral
load of HR-HPV has been estimated in a systematic manner in CIN
I–III lesions. As we expected and as previous studies have shown,
there was a wide range of viral load values over several
magnitudes, regardless of CIN grade (Peitsaro et al, 2002), but
the average of copies of HR-HPV per cell were not significantly
different in the CIN I, II and III cases (8, 17 and 6, respectively).
The same was found also for the separately calculated values of
HPV 16. The results might be influenced by the sample material,
which was paraffin-embedded, formaldehyde-fixed biopsies. In
general, it is difficult to obtain high DNA yields from such material
as compared with fresh biopsies.
In accordance with a previous publication (Peitsaro et al, 2002),
integration was detected at all stages of CIN. A real-time PCR-
based integration assay was employed, where specific primers and
probes directed to a unique region of E2 ORF and E6 ORF,
respectively, were used. The hinge region of E2 ORF, which is most
often deleted during HPV 16 integration into the host genome
(Kalantari et al, 1998), was selected to use as target to design E2
primers and probes.
Our results showed that all HPV 16 cases (totally 48) were found
to contain integrated virus genome. However, there was a higher
proportion of cases with complete integration at the CIN III grade
(nine cases) than at CIN I and II (2 and 1 cases); the average ratio
of (copy numbers of E2 gen/copy numbers of E6 gen) was not
significantly different in the three CIN grades. The reason could be,
for instance, the limited number of samples (48 samples), or the
episomal signal could arise from border areas of the biopsy that
are not yet malignant. If a microdissection could be performed, to
select only the parts of the biopsy with clear malignant properties,
it is possible that the difference in the integrated/episomal ratio
would be more significant.
As we expected, there was a significantly higher number of CIN
III samples showing very low levels of episomal compared to
integrated form (o1/100), than for the other CIN grades.
A combination of organised and opportunistic screening has
reduced the incidence of squamous carcinoma substantially during
the last decades in Sweden (Ma ¨hlck et al, 1994; Ponten et al, 1995).
In several studies, the Pap smear has been shown to have a high
false-negative rate (Macgregor et al, 1994). A review of evidence-
based data revealed that as many as 50% of precancerous cervical
lesions may be missed by a single Pap test (Sherman et al, 1994).
Another drawback of cervical cytology is its high false-positive rate
(Sherman et al, 1994). Kinney et al (1998) showed that only 30% of
women with histologically confirmed high-grade disease had
corresponding atypia in their Pap smears. Studies have shown
that 15–28% of HPV-DNA-positive women with normal cytology
develop CIN within 2 years, compared with only 1–3% of HPV-
DNA negative women (Schiffman and Castle, 2003). Against this
background, a new screening strategy for cervical cancer has been
presented in which HPV testing is combined with cytological
examinations (Walboomers et al, 1999). In addition, the abun-
dance of transient infections and lack of treatment for HPV
infections make it impractical to follow up all infected individuals.
HPV testing was identified to have higher sensitivity and equal
specificity compared to repeated Pap smear collection as a triage
for CIN II–III (Andersson et al, 2004). Viral load and integration
have been proposed, as ways of increasing the specificity of HPV
tests. Based on others results (Ylitalo et al, 2000; Moberg et al,
2004), women infected with a high viral load of HPV 16 are at
increased risk of developing cervical carcinoma in situ already
several years before diagnosis, compared to women infected with a
low viral dose. Viral load mainly seems to have relevance for HPV
16-related tumours. By using quantitative methods to measure
HPV viral load, we probably have a sensitive tool to identify
women of over-risk for cervical carcinoma. This would have
important applications for the cervical screening. Prospective
randomised studies including quantitative HPV testing are needed
on fresh material.
Vaccines emerging today are directed mainly against HPV 16
and 18. Even if vaccines were expanded to cover HPV 31 and 45,
they would still only prevent 80% of cervical cancers worldwide.
HPV vaccination is likely to significantly reduce HPV infection
and cervical cancer burden, but the need for screening of some
form is likely to remain in the foreseeable future.
ACKNOWLEDGEMENTS
We wish to thank Carmen Flores-Staino for technical assistance.
We are grateful to Quantovir AB for their gift of HPV kits used in
this study.
Type distribution, viral load and integration of HR-HPV
S Andersson et al
2199
British Journal of Cancer (2005) 92(12), 2195–2200 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sREFERENCES
Andersson S, Dillner L, Elfgren K, Mints M, Persson M, Rylander E (2004)
A comparison of the HPV test and Pap smear as a second screening
method for women with minor cytological abnormalities. Acta Obstet
Gynecol Scand (in press)
Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman
MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human
papillomavirus in cervical cancer: a worldwide perspective. International
Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer
Inst 87: 796–802
Bosch FX, Munoz N (2002) The viral etiology of cervical cancer. Virus Res
89: 183–190
Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet
JP, Kantelip B, Schaal JP, Mougin C (2003) Persistence and load of high-
risk HPV are predictors for development of high-grade cervical lesions: a
longitudinal French cohort study. Int J Cancer 106: 396–403
Davidson M, Schnitzer PG, Bulkow LR, Parkinson AJ, Schloss ML,
Fitzgerald MA, Knight JA, Murphy CM, Kiviat NB, Toomey KE (1994)
The prevalence of cervical infection with human papillomaviruses and
cervical dysplasia in Alaska Native women. J Infect Dis 169: 792–800
Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer
CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B (2002)
Population-based type-specific prevalence of high-risk human papillo-
mavirus infection in middle-aged Swedish women. J Med Virol 66:
535–541
Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME,
Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M (2003) A
comparison between real-time polymerase chain reaction and hybrid
capture 2 for human papillomavirus DNA quantitation. Cancer
Epidemiol Biomarkers Prev 12: 477–484
Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history
of cervicovaginal papillomavirus infection in young women. N Engl J
Med 338: 423–428
Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH,
Fransen-Daalmeijer N, Meijer CJ (2000) Distribution of 37 mucosotropic
HPV types in women with cytologically normal cervical smears: the
age-related patterns for high-risk and low-risk types. Int J Cancer 87:
221–227
Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P,
Andersen PK, Melbye M, Adami HO, Gyllensten UB (2000) Viral load of
human papilloma virus 16 as a determinant for development of cervical
carcinoma in situ: a nested case–control study. Lancet 355: 2189–2193
Kalantari M, Blennow E, Hagmar B, Johansson B (2001) Physical state of
HPV16 and chromosomal mapping of the integrated form in cervical
carcinomas. Diagn Mol Pathol 10: 46–54
Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B, Johansson B
(1998) Disruption of the E1 and E2 reading frames of HPV 16 in cervical
carcinoma is associated with poor prognosis. Int J Gynecol Pathol 17:
146–153
Kinney WK, Manos MM, Hurley LB, Ransley JE (1998) Where’s the high-
grade cervical neoplasia? The importance of minimally abnormal
Papanicolaou diagnoses. Obstet Gynecol 91: 973–976
Lazo PA (1997) Papillomavirus integration: prognostic marker in cervical
cancer? Am J Obstet Gynecol 176: 1121–1122
Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S,
Rush BB, Gravitt PE, Schussler JE, Schiffman M (2002) Viral load of
human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360:
228–229
Macgregor JE, Campbell MK, Mann EM, Swanson KY (1994) Screening for
cervical intraepithelial neoplasia in north east Scotland shows fall in
incidence and mortality from invasive cancer with concomitant rise in
preinvasive disease. BMJ 308: 1407–1411
Ma ¨hlck C, Jonsson H, Lenner P (1994) Pap smear screening and changes in
cervical cancer mortality in Sweden. Int J Gynecol Obstet 44: 267–272
Moberg M, Gustavsson I, Gyllensten U (2003) Real-time PCR-based system
for simultaneous quantification of human papillomavirus types asso-
ciated with high risk of cervical cancer. J Clin Microbiol 41: 3221–3228
Moberg M, Gustavsson I, Gyllensten U (2004) Type-specific associations of
human papillomavirus load with risk of developing cervical carcinoma in
situ. Int J Cancer 112: 854–859
Moberg M, Gustavsson I, Wilander E, Gyllensten U (2005) High viral loads
of human papillomavirus predict risk of invasive cervical carcinoma. Br J
Cancer 92: 891–894
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV,
Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human
papillomavirus types associated with cervical cancer. N Engl J Med 348:
518–527
Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink
AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ
(1999) Relation of human papillomavirus status to cervical lesions and
consequences for cervical-cancer screening: a prospective study. Lancet
354: 20–25
Peitsaro P, Johansson B, Syrjanen S (2002) Integrated human papilloma-
virus type 16 is frequently found in cervical cancer precursors as
demonstrated by a novel quantitative real-time PCR technique. J Clin
Microbiol 40: 886–891
Ponten J, Adami HO, Friberg LG, Gustafsson L, Miller AB, Parkin M,
Sparen P, Trichopoulos D (1995) HPV and cervical cancer. Int J Cancer
63: 317
Romanczuk H, Howley PM (1992) Disruption of either the E1 or the E2
regulatory gene of human papillomavirus type 16 increases viral
immortalization capacity. Proc Natl Acad Sci USA 89: 3159–3163
Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM,
Rush BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S (1993)
Epidemiologic evidence showing that human papillomavirus infection
causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:
958–964
Schiffman MH, Castle P (2003) Epidemiologic studies of a necessary causal
risk factor: human papillomavirus infection and cervical neoplasia. J Natl
Cancer Inst 95: E2
Schlecht NF, Trevisan A, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL,
Franco EL (2003) Viral load as a predictor of the risk of cervical
intraepithelial neoplasia. Int J Cancer 103: 519–524
Sherman ME, Schiffman M, Cox JT (2002) Effects of age and human
papilloma viral load on colposcopy triage: data from the randomized
Atypical Squamous Cells of Undetermined Significance/Low-Grade
Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer
Inst 94: 102–107
Sherman ME, Schiffman MH, Lorincz AT (1994) Toward objective quality
assurance in cervical cytopathology: correlation of cytopathologic
diagnosis with detection of high-risk human papillomavirus types. Am
J Clin Pathol 102: 182–187
Soutter WP, Fletcher A (1994) Invasive cancer of the cervix in women with
mild dyskaryosis followed up cytologically. BMJ 308: 1421–1423
Sun CA, Lai HC, Chang CC, Neih S, Yu CP, Chu TY (2001) The significance
of human papillomavirus viral load in prediction of histologic severity
and size of squamous intraepithelial lesions of uterine cervix. Gynecol
Oncol 83: 95–99
Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY (2002) Viral load of high-
risk human papillomavirus in cervical squamous intraepithelial lesions.
Int J Gynaecol Obstet 76: 41–47
Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger
ER, Nisenbaum RA, Reeves WC, Icenogle JP (1999) Human papilloma-
virus (HPV) DNA copy number is dependent on grade of cervical disease
and HPV type. J Clin Microbiol 37: 1030–1034
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is
a necessary cause of invasive cervical cancer worldwide. J Pathol 189:
12–19
Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten
J, Adami HO, Gyllensten UB, Melbye M (2000) Consistent high viral load
of human papillomavirus 16 and risk of cervical carcinoma in situ:a
nested case–control study. Lancet 355: 2194–2198
Type distribution, viral load and integration of HR-HPV
S Andersson et al
2200
British Journal of Cancer (2005) 92(12), 2195–2200 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s